Addition of Wnt3a is also sufficient to increase the growth of human RCC cells in vitro, whilst inhibition of FZD7 with shRNA is able to reduce proliferation in the human RCC cells [218], suggesting FZD7 may be an attractive therapeutic target to treat RCC. The gene discussed is WNT3A; the disease is renal cell carcinoma.